PUBLISHER: Grand View Research | PRODUCT CODE: 1609582
PUBLISHER: Grand View Research | PRODUCT CODE: 1609582
The Europe medical affairs outsourcing market size is expected to reach USD 669.1 million by 2030, registering a CAGR of 12.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing number of clinical trials and development of orphan therapies are anticipated to propel the market growth over the forecast period.
The medical affairs department separates R&D and commercial functions to reduce commercial influence on R&D due to increased scrutiny of the promotion of a therapeutic product by regulatory agencies. It acts as a liaison between the two functions, facilitating the transition of drugs from R&D to commercial. Such stringent regulations are expected to drive the outsourcing of medical affairs activities to more efficient third-parties.
The requirement of medical affairs service providers has increased for preparation of drafts for new patents owing to patent expiration in the industry. In addition, pharmaceutical, biopharmaceutical, and medical device companies are outsourcing these services to contract research organizations to save cost and avail professional medical affairs services.